Antimycotic gel with high active substance release

Details Antimycotic gel with high active substance release Antimycotic gel with high active substance release

2006-03-28

2006-03-28

Webman, Edward J. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Matrices

C424S404000, C424S405000, C514S944000

Reexamination Certificate

active

07018656

ABSTRACT:
A pharmaceutical preparation comprising a hydrophilic gel-forming agent, water and a compound of the formula Iis suitable for the treatment and prophylaxis of dermatomycoses.

REFERENCES:
patent: 3968118 (1976-07-01), Lohaus et al.
patent: 4185106 (1980-01-01), Dittmar et al.
patent: 4699924 (1987-10-01), Durrant et al.
patent: 4797409 (1989-01-01), Lohaus et al.
patent: 4957730 (1990-09-01), Bohn et al.
patent: 5066484 (1991-11-01), Castrogiovanni et al.
patent: 5071639 (1991-12-01), Soyama et al.
patent: 5120530 (1992-06-01), Ferro et al.
patent: 5132107 (1992-07-01), Lange
patent: 5264206 (1993-11-01), Bohn et al.
patent: 5346692 (1994-09-01), Wohlrab et al.
patent: 5356907 (1994-10-01), Clemence et al.
patent: 5395843 (1995-03-01), Clemence et al.
patent: 5494658 (1996-02-01), Hänel et al.
patent: 5510100 (1996-04-01), Picard et al.
patent: 5559130 (1996-09-01), Clemence et al.
patent: 5603939 (1997-02-01), Ser
patent: 5609854 (1997-03-01), Guerrero et al.
patent: 5612327 (1997-03-01), Makino et al.
patent: 5650145 (1997-07-01), Saint-Leger
patent: 5675013 (1997-10-01), Hani et al.
patent: 5683681 (1997-11-01), Ramin et al.
patent: 5753600 (1998-05-01), Kamegai et al.
patent: 5756108 (1998-05-01), Ribier et al.
patent: 5866105 (1999-02-01), Richter et al.
patent: 6162420 (2000-12-01), Bohn et al.
patent: 6455551 (2002-09-01), Kraemer et al.
patent: 6469033 (2002-10-01), Bohn et al.
patent: 2003/0086881 (2003-05-01), Bohn et al.
patent: 716 208 (1998-04-01), None
patent: 2134293 (1995-04-01), None
patent: 2134304 (1995-04-01), None
patent: 31 40 954 (1983-05-01), None
patent: 38 26 914 (1990-02-01), None
patent: 0 218 410 (1987-04-01), None
patent: 0 241 918 (1987-10-01), None
patent: 0 313 305 (1989-04-01), None
patent: 0 381 446 (1990-08-01), None
patent: 0 515 312 (1992-11-01), None
patent: 0 646 369 (1995-04-01), None
patent: 0 649 660 (1995-04-01), None
patent: 0 680 745 (1995-11-01), None
patent: 0 680 745 (1995-11-01), None
patent: 0 771 187 (1997-05-01), None
patent: 2 618 068 (1989-01-01), None
patent: 2 685 638 (1993-07-01), None
patent: 2 685 867 (1993-07-01), None
patent: 2 694 694 (1994-02-01), None
patent: 2 207 051 (1989-01-01), None
patent: 2 208 149 (1989-03-01), None
patent: 202098 (1990-03-01), None
patent: 208 007 (1993-07-01), None
patent: 61-69721 (1986-04-01), None
patent: 95-325488 (1995-08-01), None
patent: WO 87 02580 (1987-05-01), None
patent: 94/05256 (1994-03-01), None
patent: WO 95/17165 (1995-06-01), None
patent: 96/02226 (1996-02-01), None
patent: 96/13247 (1996-05-01), None
patent: WO 96 19186 (1996-06-01), None
patent: WO 96 29045 (1996-09-01), None
patent: WO 96/29056 (1996-09-01), None
patent: 97/20560 (1997-06-01), None
patent: 98/13009 (1998-04-01), None
patent: 98/13043 (1998-04-01), None
patent: WO 98/13042 (1998-04-01), None
patent: WO 99 39680 (1999-08-01), None
patent: WO 99 49835 (1999-10-01), None
Yoshimasa et al., “The sebum lipid assimilation and the growth inhibition ofPityrosporum ovale(1streport), ” J. SCCJ, vol. 22(3), pp. 165-170 (1988).
Saint-Leger et al., “The role of the resident microflora in the pathogenesis of dandruff,” J. Soc. Cosmet. Chem., vol. 40, pp. 109-117 (1989).
H. Hänel et al., “Evaluation of Fungicidal Action in Vitro and in a Skin Model Considering the Influence of Penetration Kinetics of Various Standard Antimycotics,”Annals New York Academy of Sciences,544:329-337 (1988).
P.C. Braga et al., “Inhibition ofCandida albicansAdhesiveness to Human Buccal and Vaginal Cells by Sub-inhibitory Concentrations of Rilopirox,”Arzneim.-Forsch./Drug Res.,45(1):84-87 (1995).
H. Hänel et al., “A Comparison of Bifonazole and Ciclopiroxolamine: In Vitro, Animal, and Clinical Studies,”Mycoses31(12):632-640 (1988).
W. Raether et al., “Rilopriox-a New Hydroxypyridone Antifungal with Fungicidal Properties,”Mycoses,33(4):191-202 (1990).
H. Hanel et al., Treatment of seborrhoic eczema using an antimycotic with antiphlogistic properties,Mycoses 34(Suppl.):91-93 (1991).
R. Aly et al., “Common Superficial Fungal Infections in Patients with AIDS,”CID22(Supp. 2):S128-S132 (1996).
E. Grosshans et al., “L'Eczema Seborrheique (La Pityrosporose),” Ann. Dermatol. Venereol., 115:79-86 (1988) (with English translation of abstract).
Martindale The Extra Pharmacopoeia 30thEd., London The Pharmaceutical Press 1993, pp. 332, 1609.
Montana, et al., “A Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Fungoid Tincture® in Patients with Distal Subungual Onychmycosis of the Toes,”Cutis,53:313-316 (1994).
J. Shapiro et al., “Medicated Shampoos,”Clinics in Dermatology,14:123-128 (1996).
Derwent Abstract of FR 2 685 638.
Derwent Abstract of WO 96/2226A1.
Japanese Abstract No. 07082126A, Mar. 28, 1995.
Derwent Abstract of EP 0 680 745 A2.
Derwent Abstract of EP 0 649 660 A2.
Derwent Abstract of EP 0 646 369 A1.
Derwent Abstract of FR 2 618 068.
Derwent Abstract of JP 61-69721.
Translation of EP 0 771 187.
Rivalland, P., “Evaluation of the Antifungal Activity of Two Derivatives and In Vivo Innocuity Test of Shampooings with Regard to Antidandruff Formulations,” Abstract, Int. J. Cosmet. Sci. (1994), vol. 16(2), pp. 77-83.
Abstract of FR 2 685 867 A1.
Abstract of FR 2 694 694 A1.
Translation of Thorel (FR 2 685 867 A1) with Certification of Translation (12 pages total).
Abrams et al., “Ciclopirox Olamine: A Hydroxypyridone Antifungal Agent,”Clinics In Dermatology,vol. 9, pp. 471-477 (1992).
Amos et al., “Clinical efficacy of Polytar AF (Fongitar) and Nizoral Scalp Treatments in Patients with Dandruff/Seborrhoeic Dermatitis,”Journal of Dermatological Treatment,vol. 5, pp. 127-130 (1994).
Corte et al., “Topische Anwendung einer 0.1%igen Ciclopiroxolamin-Lösung zur Behandlung der Pityriasis versicolor, Topical Application of a 0.1% Ciclopiroxolamine Solution for the Treatment of Pityriasis versicolor,”Mycoses,vol. 32, No. 4, pp. 200-203 (1989). (English Abstract).
Cullen et al., “Treatment of Tinea Versicolor with a New Antifungal Agent, Ciclopirox Olamine Cream 1%,”Clinical Therapeutics,vol. 7, No. 5, pp. 574-583 (1985).
Faergemann, J., “Pityriasis Versicolor,”Seminars in Dermatology, vol. 12, No. 4, pp. 276-279 (1993).
Plewig et al., “Seborrheic Dermatitis,”FitzPatrick's Dermatology in General Medicine, 5thEd.,Ch. 126, pp. 1-17 CD-Rom (1999).
Przekop et al., “Ciclopirox Olamine, An Antifungal Modulator of Neutrophil Function and Infiltrate in Cutaneous Inflammation,” J. Investigative Dermatology, vol. 102, No. 4, (SID Abstracts) p. 593 (1994).
Schofer, H., “Therapie des seborrhoischen Ekzems bei HIV-Infektion,” Forschung und Praxis, 98 Seite III (1990).
Shuster, S., “Dandruff, Seborrhoeic Dermatitis, and Pityrosporum Ovale,”Cosmetics and Toiletries,vol. 103, pp. 87-91 (1988).
“Scaly Dermatoses,”Handbook of Nonprescription Drugs,American Pharm. Assoc., Ch. 26, pp. 550-552 (1996).
“Seborrheic Dermatitis and Dandruff,” Manual of Dermatologic Therapeutics, 5thEd., Ch. 29, pp. 164-167 (1995).

Affiliated with

Also associated with

Rating

Antimycotic gel with high active substance release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antimycotic gel with high active substance release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimycotic gel with high active substance release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3604489